SINOPHARM: Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%
SINOPHARM announced the performance of Sinopharm Accord for the first three quarters of 2025, with operating revenue of 55.124 billion yuan, a year-on-year decrease of 2.38%; net profit attributable to the parent company of 959 million yuan, a year-on-year decrease of 10.18%; and basic earnings per share of 1.72 yuan. In the third quarter of 2025, operating revenue was 18.328 billion yuan, a year-on-year decrease of 1.89%; net profit attributable to the parent company was 291 million yuan, a year-on-year decrease of 9.58%
According to the Zhitong Finance APP, SINOPHARM (01099) announced the performance of Sinopharm Accord for the first three quarters of 2025, achieving operating revenue of 55.124 billion yuan, a year-on-year decrease of 2.38%; the net profit attributable to shareholders of the listed company was 959 million yuan, a year-on-year decrease of 10.18%; basic earnings per share were 1.72 yuan. In the third quarter of 2025, the operating revenue was 18.328 billion yuan, a year-on-year decrease of 1.89%; the net profit attributable to shareholders of the listed company was 291 million yuan, a year-on-year decrease of 9.58%
